Coloradans are being told that Senate Bill 26-098 (State and Local Noise Abatement Authority) is about “local control.” That it simply allows cities to set their own standards. That it restores ...

U.S.-based Yarrow Bioscience is branching out, picking an autoimmune thyroid disease drug from China as its lead candidate. Through a potential $1.37 billion deal, New York-headquartered Yarrow gains ...

The Department of Education (DepEd) remains steadfast in promoting transparency, integrity, and accountability by making basic education data accessible to the public which empowers internal and ...

PRAGMATICA-LUNG (SWOG S2302): A prospective, randomized study of ramucirumab plus pembrolizumab versus standard of care for participants previously treated with immunotherapy for stage IV or recurrent ...

Results from the RELATIVITY-098 trial of Opdualag in the adjuvant treatment of completely resected stage III-IV melanoma did not meet the primary endpoint of recurrence-free survival. The Phase III ...

Bristol Myers Squibb announced the phase 3 RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) for the adjuvant treatment of patients with completely resected stage III-IV ...

The failure in adjuvant melanoma could cause BMS and Opdualag to miss out on a market opportunity that is nearly twice as large as its current approved indication, according to analysts. Bristol Myers ...

RELATIVITY-098 is a randomized Phase 3, double-blind study evaluating adjuvant immunotherapy with Opdualag, the fixed-dose combination of nivolumab and relatlimab, compared to Opdivo monotherapy after ...

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag™ (nivolumab and relatlimab-rmbw) for the adjuvant treatment of ...

remove-circle Internet Archive's in-browser bookreader "theater" requires JavaScript to be enabled. It appears your browser does not have it turned on. Please see ...